Research

School

School of Biomedical and Pharmaceutical Sciences

Title

Professor,PhD supervisor/Master supervisor

Research Interests

Pathogenesis and drug development of metabolic chronic diseases (mainly focus on tumors, obesity, autoimmunity and reproduction)

Home Page

https://yzw.gdut.edu.cn/info/1129/1575.htm

Contacts

Tel：18027330798 Email: fli@gdut.edu.cn

Personal Introduction

Li Fanghong, Professor, doctoral supervisor, national distinguished expert, the first core member of innovation and entrepreneurship team of Pearl River talent plan of Guangdong Province, and special professor of 100 talents plan of Guangdong University of technology. She graduated from the Department of preventive medicine, China Medical University in 1990. In 1995, she obtained a master's degree in Sun Yat—sen University and worked there. In 1998, he was sent to National University of Singapore for WHO project training. From 2000 to 2006, he worked as a research assistant at the School of medicine in University of Boston and Pittsburgh. In 2006, he entered the pathology department of Saint Barnabas Medical Center in the United States and completed four years of rigorous training for resident doctor in histopathology and clinical pathology. From 2010 to 2011, he worked in the Department of Pathology of Johns Hopkins Medical College in the United States as a gynecological pathology specialist. Professor Li has been engaged in the research of pathology, toxicology, bone metabolism, molecular mechanism of obesity, diabetes and cancer, drug development and standardization of pathological diagnosis for many years. As the first author, he has published many papers in a series of professional magazines with high impact factors, such as Nature Medicine, American Journal of Surgical Pathology, American Journal of Physiology, Journal of Biological Chemistry, Journal of Bone and Mineral Research，International Journal of Surgical Pathology, etc.

Education

July 1985 to July 1990: Bachelor of Public Health, China Medical University

July 1992 to July 1995: Master of Preventive Medicine, Sun Yat-sen University Zhongshan School of Medicine

July 2006 to July 2010: Doctor of Medicine, Department of Pathology, Saint Barnabas Medical Center, USA

Work Experience

July 2010 to October 2011: Pathologist, Pathology Department, Johns Hopkins Medical College, USA

November 2011 to July 2017: Professor, Nanjing Medical University

November 2015 to December 2016 Professor, South China University of Technology

January 2017 to present: Professor, Guangdong University of Technology

Part-time Academic Job

N/A

Main Honor

National Distinguished Expert

Talent of innovation and entrepreneurship recognized by Jiangsu Province

The first core member of the innovation and entrepreneurship team of the Pearl River Talent Program in Guangdong Province

Outstanding Talents in Guangzhou Development Zone

Main Achievements

1. Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X, Zhao AZ*，ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity.，J Clin Invest，2017.5.1，127(5):1757-1771.

2. Cheng, Lixian，Shi, Hui，Jin, Yan，Li, Xiaoxi，Pan, Jinshun，Lai, Yimei，Lin, Yan，Jin, Ya，Roy, Gaurab，Zhao, Allan*，Li, Fanghong*，Adiponect in Deficiency Leads to Female Subfertility and Ovarian Dysfunctions in Mice.，Endocrinology，2016.12.01, 57(12): 4875~4887.

3. Li, Jie，Wei, Dong，McCrory, Mark A，Szalai, Alexander J，Yang, Gangyi，Li, Ling，Li, Fanghong*，Zhao, Allan Z *，Human C-reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in the CNS.，Biochem J，2016.05.1，473(9): 1215~1224.

4. Zhu, Yan，Yu, Meining，Ma, Luyao，Xu, Hai，Li, Fanghong Rose*，Choriocarcinoma-associated pulmonary thromboembolism and pulmonary hypertension: a case report.，J Biomed Res，2016.05.01，30(3): 243~247.

5. Pan J，Cheng L，Bi X，Zhang X， Liu S，Bai X，Li F，Zhao AZ*， Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production.， Sci Rep，2015.10.15，5:14958.

6. Zeng, Fangxin，Shi, Jinyu，Long, Yang，Tian, Haoming，Li,Xiaoxi，Zhao, Allan Z，Li, Rose Fanghong*，Chen, Tao *，Adiponectin and Endometrial Cancer: A Systematic Review and Meta-Analysis.，Cellular Physiology and Biochemistry.，2015.01.01，36(4): 1670~1678.

7. Chen, Ke(#) ，Li, Fanghong(#)，Li, Ji，Cai, Hongbo，Strom, Steven，Bisello, Alessandro，Kelley, David E，Friedman-Einat, Miriam，Skibinski, Gregory A，McCrory, Mark A，Szalai, Alexander J，Zhao, Allan Z，Induction of leptin resistance through direct interaction of C-reactive protein with leptin.，Nat Med，2006.04.01，12(4): 425~432.

8. Li, Jie(#)，Li, Fanghong R(#)，Wei, Dong，Jia, Wei，Kang, Jing X，Stefanovic-Racic, Maja，Dai, Yifan，Zhao, Allan Z*，Endogenous omega-3 polyunsaturated fatty acid production confers resistance to obesity, dyslipidemia, and diabetes in mice.，Molecular Endocrinology.，2014.08.01，28(8): 1316~1328.

9. Li, Rose Fanghong(#)，Gupta, Mamta，McCluggage, W Glenn，Ronnett, Brigitte M，Embryonal rhabdomyosarcoma (botryoid type) of the uterine corpus and cervix in adult women: report of a case series and review of the literature.，Am J Surg Pathol，2013.3.01，37(3): 344~355.

10. Li, Fanghong(#)，Chung, Hoyeon，Reddy, Sakamuri V，Lu, Ganwei，Kurihara, Noriyoshi，Zhao, Allan Z*，Roodman, G David，Annexin II stimulates RANKL expression through MAPK.，J Bone Miner Res，2005.07.01，20(7): 1161~1167. Patents authorized in rencent years: 1 GENETICALLY ENGINEERED BACTERIUM FOR TREATMENT OF BREAST CANCER, METHOD FOR CONSTRUCTING THE BACTERIUM, AND APPLICATIONS THEREO, invention patent, United States, patent number 14766558, authorization announcement date 2017-09-13

2 APPLICATION OF AN ATTENUATED SALMONELLA TYPHIMURIUM Patent for invention, United States, patent number 9439934, authorization announcement date 2016-08-24

3 GENETICALLY ENGINEERED BACTERIUM FOR TREATMENT OF BREAST CANCER, invention patent, Australia, patent number 2014223112, authorization announcement date 2017-02-03

4 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of drugs for the treatment of pancreatic cancer, invention patent, China, Patent No.

5 A genetically engineered bacterium for the treatment of breast cancer and its construction method and application, invention patent, China, patent number ZL201310062253.7, authorization announcement date 2014-12-31

6 Application of attenuated Salmonella typhimurium and its genetically engineered bacteria in the preparation of drugs for the treatment of prostate cancer, invention patent, China, patent number ZL201410183149.8, authorization announcement date 2018-08-08

7 COMPOSTITIONS FOR BLOCKING THE INHIBITORY EFFECT OF Patent for invention, United States, Patent No. 7629315 Authorization announcement date 2009-12-08

Patent pending:

1 Application of genetically engineered bacteria VNP20009-M in the preparation of drugs for the prevention and treatment of lung cancer, invention patent, Hong Kong, China, patent application number 18100076.7, application date 2018-01-03, preliminary review stage

2 Application of genetically engineered bacteria VNP20009-M in the preparation of drugs for the treatment of malignant sarcoma, invention patent, Hong Kong, China, patent application number 18101397.7, application date 2018-01-29, preliminary review stage

3 Application of genetically engineered bacteria VNP20009-M in the preparation of drugs for preventing and treating cancer metastasis, invention patent, China, patent application number 2016100812709, application date 2016-02-05, substantive review stage

Main Projects

1. The research and development of Phase 1 and Phase 2 clinical trials of biological anti-cancer drug SGN1 in the treatment of advanced malignant tumors,Guangdong Provincial Department of Science and Technology, Pearl River talent plan, 2016-202,20 million, core member

2. In vivo research on adiponectin and endometrial cancer occurrence and development, National Natural Science Foundation of China, RMB 620,000, January 2014-December 2017, host

3. Research on molecular association between lipid metabolism disorder and spermatogenesis disorder, National Key Basic Research and Development Program, 2013-2017, 21 million, participant

Research Team

The team has a number of teachers graduated from key universities, as well as PhD students who can help supervise the research work of graduate students.